financetom
Business
financetom
/
Business
/
Mexican cement maker Cemex's core profits slip on weaker local market
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mexican cement maker Cemex's core profits slip on weaker local market
May 25, 2025 7:56 PM

MEXICO CITY, April 28 (Reuters) - Mexican cement maker

Cemex reported an 18% dip in its core earnings for the first

quarter on Monday, driven largely by headwinds in the local

market.

Cemex reported earnings before interest, taxes, depreciation

and amortization of $601 million, in line with estimates, due to

a weaker peso currency and a dip in volumes at home, it said in

a filing.

The peso caused a $65 million hit to EBITDA, Cemex said,

while volumes dropped in Mexico due to a rush last year to

finish government infrastructure projects before presidential

elections.

The firm expects its full-year EBITDA to come in upward of

$3 billion, and held that forecast on Monday.

The U.S. was Cemex's largest market by sales in the first

quarter - followed by Europe, the Middle East and Africa - and

then Mexico.

Total sales slipped 7% to $3.65 billion, also in line with

the LSEG-compiled estimate, as higher prices failed to fully

offset lower volumes.

Cement and ready-mix volumes ticked up slightly, though

aggregates came down 4%, Cemex said.

The results come after Cemex's long-time CEO Fernando

Gonzalez retired at the beginning of this month, with Cemex USA

head Jaime Muguiro replacing him.

The firm has shifted its focus in recent years toward the

U.S., selling off non-core businesses including in Guatemala,

the Philippines and the Dominican Republic. In February,

Bloomberg News reported that Cemex was gauging interest for a

potential sale of its Colombia unit.

Cemex said on Monday it was still eying small- to mid-size

acquisitions in the United States.

In the quarter, Cemex's net profit nearly tripled to $734

million, boosted by the Dominican Republic sale. According to

Cemex, $618 million of its net profit in the quarter came from

discontinued operations.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved